Re:NewCell Valuation
Is RENEW undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of RENEW when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate RENEW's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate RENEW's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RENEW?
Other financial metrics that can be useful for relative valuation.
What is RENEW's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | SEK 219.03m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.1x |
Enterprise Value/EBITDA | -4.1x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does RENEW's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.4x | ||
CIRCHE CirChem | 9.1x | n/a | SEK 81.7m |
ECO B EcoRub | 2.3x | n/a | SEK 33.3m |
NEXAM Nexam Chemical Holding | 2x | 14.2% | SEK 414.3m |
DURC B Duroc | 0.2x | n/a | SEK 663.0m |
RENEW Re:NewCell | 1.1x | 83.0% | SEK 219.0m |
Price-To-Sales vs Peers: RENEW is good value based on its Price-To-Sales Ratio (1.1x) compared to the peer average (8.7x).
Price to Earnings Ratio vs Industry
How does RENEW's PE Ratio compare vs other companies in the European Chemicals Industry?
Price-To-Sales vs Industry: RENEW is good value based on its Price-To-Sales Ratio (1.1x) compared to the European Chemicals industry average (1.1x).
Price to Sales Ratio vs Fair Ratio
What is RENEW's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.1x |
Fair PS Ratio | 1.1x |
Price-To-Sales vs Fair Ratio: RENEW is good value based on its Price-To-Sales Ratio (1.1x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Jul ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Jun ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
May ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Apr ’25 | n/a | SEK 40.00 0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Mar ’25 | SEK 5.30 | SEK 40.00 +654.7% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Feb ’25 | SEK 8.88 | SEK 40.00 +350.5% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Jan ’25 | SEK 7.61 | SEK 40.00 +426.0% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Dec ’24 | SEK 7.57 | SEK 40.00 +428.4% | 75.0% | SEK 70.00 | SEK 10.00 | n/a | 2 |
Nov ’24 | SEK 10.92 | SEK 81.00 +641.8% | 81.5% | SEK 147.00 | SEK 15.00 | n/a | 2 |
Oct ’24 | SEK 67.90 | SEK 166.33 +145.0% | 14.4% | SEK 200.00 | SEK 147.00 | n/a | 3 |
Sep ’24 | SEK 86.60 | SEK 166.33 +92.1% | 14.4% | SEK 200.00 | SEK 147.00 | n/a | 3 |
Aug ’24 | SEK 79.65 | SEK 206.33 +159.1% | 24.8% | SEK 272.00 | SEK 147.00 | n/a | 3 |
Jul ’24 | SEK 80.20 | SEK 197.67 +146.5% | 31.2% | SEK 272.00 | SEK 121.00 | n/a | 3 |
Jun ’24 | SEK 76.70 | SEK 197.67 +157.7% | 31.2% | SEK 272.00 | SEK 121.00 | n/a | 3 |
May ’24 | SEK 80.35 | SEK 203.67 +153.5% | 34.7% | SEK 292.00 | SEK 119.00 | n/a | 3 |
Apr ’24 | SEK 81.30 | SEK 224.00 +175.5% | 30.6% | SEK 292.00 | SEK 130.00 | n/a | 3 |
Mar ’24 | SEK 92.00 | SEK 224.00 +143.5% | 30.6% | SEK 292.00 | SEK 130.00 | SEK 5.30 | 3 |
Feb ’24 | SEK 95.35 | SEK 181.00 +89.8% | 38.1% | SEK 250.00 | SEK 112.00 | SEK 8.88 | 2 |
Jan ’24 | SEK 72.90 | SEK 181.00 +148.3% | 38.1% | SEK 250.00 | SEK 112.00 | SEK 7.61 | 2 |
Oct ’23 | SEK 72.00 | SEK 275.00 +281.9% | 9.1% | SEK 300.00 | SEK 250.00 | SEK 67.90 | 2 |
Sep ’23 | SEK 89.30 | SEK 275.00 +208.0% | 9.1% | SEK 300.00 | SEK 250.00 | SEK 86.60 | 2 |
Aug ’23 | SEK 100.30 | SEK 275.00 +174.2% | 9.1% | SEK 300.00 | SEK 250.00 | SEK 79.65 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.